Testing and genotyping of high-risk human papillomavirus by the cobas HPV test and the Hybrid Capture 2 high-risk HPV dna test using cervical and vaginal samples

Journal of Clinical Microbiology

Volumn 52, Issue 5, 2014, Pages 1720-1723

  Pyne, Michael T ^a   Law, Christian ^b   Hillyard, David R ^a,c   Schlaberg, Robert ^a,c  

^a ARUP INSTITUTE FOR CLINICAL AND EXPERIMENTAL PATHOLOGY   (United States)

^b ARUP LABORATORIES   (United States)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN BETA CHAIN; VIRUS DNA;

ADULT; AGED; ARTICLE; CANCER SCREENING; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; GENOTYPE; HUMAN; HUMAN PAPILLOMAVIRUS DNA TEST; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; MAJOR CLINICAL STUDY; NONHUMAN; PRIORITY JOURNAL; REPRODUCIBILITY; UTERINE CERVIX CANCER; UTERINE CERVIX CYTOLOGY; VAGINA CYTOLOGY; VERY ELDERLY; VIRUS DETECTION; VIRUS STRAIN; VIRUS TITRATION; VIRUS VIRULENCE; WART VIRUS; EARLY DIAGNOSIS; GENETICS; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; PROCEDURES; UTERINE CERVIX; VAGINA; VAGINA SMEAR; VIROLOGY;

ADULT; AGED; CERVIX UTERI; DNA, VIRAL; EARLY DETECTION OF CANCER; FEMALE; GENOTYPE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMAN PAPILLOMAVIRUS DNA TESTS; HUMANS; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; VAGINA; VAGINAL SMEARS;

EID: 84899495499     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.03308-13     Document Type: Article

References (16)

1. Siegel R, Naishadham D, Jemal A. 2013. Cancer statistics, 2013. CACancer J. Clin. 63:11-30. http://dx.doi.org/10.3322/caac.21166.
2. Saslow D, Solomon D, Lawson HW, Killackey M, Kulasingam SL, Cain J, Garcia FA, Moriarty AT, Waxman AG, Wilbur DC, Wentzensen N, Downs LS, Jr, Spitzer M, Moscicki AB, Franco EL, Stoler MH, Schiffman M, Castle PE, Myers ER, American Cancer Society, American Society for Colposcopy and Cervical Pathology, American Society for Clinical Pathology. 2012. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. Am. J. Clin. Pathol. 137:516-542. http://dx.doi.org/10.1309/ AJCPTGD94EVRSJCG.
3. Massad LS, Einstein MH, Huh WK, Katki HA, Kinney WK, Schiffman M, Solomon D, Wentzensen N, Lawson HW, 2012 Consensus Guidelines Conference. 2013. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. J. Low. Genit. Tract Dis. 17:S1-S27. http://dx.doi.org/10.1097/LGT.0b013e318287d329.
4. Moyer VA, U. S. Preventive Services Task Force. 2012. Screening for cervical cancer: U. S. Preventive Services Task Force recommendation statement. Ann. Intern. Med. 156:880-891:W312. http://dx.doi.org/10.7326/0003-4819-156-12- 201206190-00424.
5. Digene Corporation. 2013. Hybrid Capture 2 High-Risk HPV DNA Test package insert no. L00665 rev. 2. Qiagen, Gaithersburg, MD.
6. Roche Molecular Systems. 2011. cobas HPV Test. Doc Rev. 1.0 package insert. Roche Molecular Systems, Branchburg, NJ.
7. Gage JC, Sadorra M, Lamere BJ, Kail R, Aldrich C, Kinney W, Fetterman B, Lorey T, Schiffman M, Castle PE, PaP Cohort Study Group. 2012. Comparison of the cobas human papillomavirus (HPV) test with the hybrid capture 2 and linear array HPV DNA tests. J. Clin. Microbiol. 50:61-65. http://dx.doi.org/10.1128/ JCM.05989-11.
8. Rao A, Young S, Krevolin M, Sun R, Purner MB, Sharma A, Behrens CM. 2012. Comparison of cobas human papillomavirus test results from primary versus secondary vials of PreservCyt specimens and evaluation of potential cross-contamination. Cancer Cytopathol. 120:380-389. http://dx.doi.org/10.1002/ cncy.21213.
9. Cogliano V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, WHO International Agency for Research on Cancer. 2005. Carcinogenicity of human papillomaviruses. Lancet Oncol. 6:204. http://dx.doi.org/10.1016/S1470-2045 (05) 70086-3.
10. Castle PE, Solomon D, Wheeler CM, Gravitt PE, Wacholder S, Schiffman M. 2008. Human papillomavirus genotype specificity of hybrid capture 2. J. Clin. Microbiol. 46:2595-2604. http://dx.doi.org/10.1128/JCM.00824-08.
11. Poljak M, Marin IJ, Seme K, Vince A. 2002. Hybrid Capture II HPV Test detects at least 15 human papillomavirus genotypes not included in its current high-risk probe cocktail. J. Clin. Virol. 25(Suppl 3):S89-S97. http://dx.doi.org/10.1016/S1386-6532 (02) 00187-7.
12. Park Y, Lee E, Choi J, Jeong S, Kim HS. 2012. Comparison of the Abbott RealTime High-Risk Human Papillomavirus (HPV), Roche Cobas HPV, and Hybrid Capture 2 assays to direct sequencing and genotyping of HPV DNA. J. Clin. Microbiol. 50:2359-2365. http://dx.doi.org/10.1128/JCM.00337-12.
13. Wong AA, Fuller J, Pabbaraju K, Wong S, Zahariadis G. 2012. Comparison of the Hybrid Capture 2 and cobas 4800 tests for detection of high-risk human papillomavirus in specimens collected in Preserv-Cyt medium. J. Clin. Microbiol. 50:25-29. http://dx.doi.org/10.1128/JCM.05400-11.
14. Wright TC, Jr, Stoler MH, Behrens CM, Apple R, Derion T, Wright TL. 2012. The ATHENA human papillomavirus study: design, methods, and baseline results. Am. J. Obstet. Gynecol. 206:46.e1-46.e11. http://dx.doi.org/10.1016/j.ajog.2011. 07.024.
15. Lindemann ML, Dominguez MJ, de Antonio JC, Sandri MT, Tricca A, Sideri M, Khiri H, Ravet S, Boyle S, Aldrich C, Halfon P. 2012. Analytical comparison of the cobas HPV Test with Hybrid Capture 2 for the detection of high-risk HPV genotypes. J. Mol. Diagn. 14:65-70. http://dx.doi.org/10.1016/j.jmoldx.2011.09. 005.
16. Martínez SB, Palomares JC, Artura A, Parra M, Cabezas JL, Romo JM, Martín-Mazuelos E. 2012. Comparison of the Cobas 4800 Human Papillomavirus test against a combination of the Amplicor Human Papillomavirus and the Linear Array tests for detection of HPV types 16 and 18 in cervical samples. J. Virol. Methods 180:7-10. http://dx.doi.org/10.1016/j.jviromet.2011. 12.002.